These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 26871298)

  • 1. Fluorescence-Based Transport Assays Revisited in a Human Renal Proximal Tubule Cell Line.
    Caetano-Pinto P; Janssen MJ; Gijzen L; Verscheijden L; Wilmer MJ; Masereeuw R
    Mol Pharm; 2016 Mar; 13(3):933-44. PubMed ID: 26871298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cetuximab Prevents Methotrexate-Induced Cytotoxicity in Vitro through Epidermal Growth Factor Dependent Regulation of Renal Drug Transporters.
    Caetano-Pinto P; Jamalpoor A; Ham J; Goumenou A; Mommersteeg M; Pijnenburg D; Ruijtenbeek R; Sanchez-Romero N; van Zelst B; Heil SG; Jansen J; Wilmer MJ; van Herpen CML; Masereeuw R
    Mol Pharm; 2017 Jun; 14(6):2147-2157. PubMed ID: 28493713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of efflux transporters on the transport of highly toxic aconitine, mesaconitine, hypaconitine, and their hydrolysates, as determined in cultured Caco-2 and transfected MDCKII cells.
    Ye L; Yang X; Yang Z; Gao S; Yin T; Liu W; Wang F; Hu M; Liu Z
    Toxicol Lett; 2013 Feb; 216(2-3):86-99. PubMed ID: 23200901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proximal tubular efflux transporters involved in renal excretion of p-cresyl sulfate and p-cresyl glucuronide: Implications for chronic kidney disease pathophysiology.
    Mutsaers HA; Caetano-Pinto P; Seegers AE; Dankers AC; van den Broek PH; Wetzels JF; van den Brand JA; van den Heuvel LP; Hoenderop JG; Wilmer MJ; Masereeuw R
    Toxicol In Vitro; 2015 Oct; 29(7):1868-77. PubMed ID: 26216510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening of Drug-Transporter Interactions in a 3D Microfluidic Renal Proximal Tubule on a Chip.
    Vriend J; Nieskens TTG; Vormann MK; van den Berge BT; van den Heuvel A; Russel FGM; Suter-Dick L; Lanz HL; Vulto P; Masereeuw R; Wilmer MJ
    AAPS J; 2018 Jul; 20(5):87. PubMed ID: 30051196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro assessment of the interactions of dopamine β-hydroxylase inhibitors with human P-glycoprotein and Breast Cancer Resistance Protein.
    Bicker J; Alves G; Fortuna A; Soares-da-Silva P; Falcão A
    Eur J Pharm Sci; 2018 May; 117():35-40. PubMed ID: 29428540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction Studies of Resolvin E1 Analog (RX-10045) with Efflux Transporters.
    Cholkar K; Trinh HM; Vadlapudi AD; Wang Z; Pal D; Mitra AK
    J Ocul Pharmacol Ther; 2015 May; 31(4):248-55. PubMed ID: 25844889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A morphological and functional comparison of proximal tubule cell lines established from human urine and kidney tissue.
    Jansen J; Schophuizen CMS; Wilmer MJ; Lahham SHM; Mutsaers HAM; Wetzels JFM; Bank RA; van den Heuvel LP; Hoenderop JG; Masereeuw R
    Exp Cell Res; 2014 Apr; 323(1):87-99. PubMed ID: 24560744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tetrahydrocannabinol and Its Major Metabolites Are Not (or Are Poor) Substrates or Inhibitors of Human P-Glycoprotein [ATP-Binding Cassette (ABC) B1] and Breast Cancer Resistance Protein (ABCG2).
    Chen X; Unadkat JD; Mao Q
    Drug Metab Dispos; 2021 Oct; 49(10):910-918. PubMed ID: 34326138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemical inhibition and stable knock-down of efflux transporters leads to reduced glucuronidation of wushanicaritin in UGT1A1-overexpressing HeLa cells: the role of breast cancer resistance protein (BCRP) and multidrug resistance-associated proteins (MRPs) in the excretion of glucuronides.
    Qin Z; Li S; Yao Z; Hong X; Wu B; Krausz KW; Gonzalez FJ; Gao H; Yao X
    Food Funct; 2018 Mar; 9(3):1410-1423. PubMed ID: 29318243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aristolochic acid I is a substrate of BCRP but not P-glycoprotein or MRP2.
    Ma L; Qin Y; Shen Z; Bi H; Hu H; Huang M; Zhou H; Yu L; Jiang H; Zeng S
    J Ethnopharmacol; 2015 Aug; 172():430-5. PubMed ID: 26183576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between Membrane Protein Expression Levels and Transcellular Transport Activity for Breast Cancer Resistance Protein.
    Liu H; Huang L; Li Y; Fu T; Sun X; Zhang YY; Gao R; Chen Q; Zhang W; Sahi J; Summerfield S; Dong K
    Drug Metab Dispos; 2017 May; 45(5):449-456. PubMed ID: 28209803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new mechanism for increasing the oral bioavailability of scutellarin with Cremophor EL: Activation of MRP3 with concurrent inhibition of MRP2 and BCRP.
    Xiao L; Yi T; Chen M; Lam CW; Zhou H
    Eur J Pharm Sci; 2016 Oct; 93():456-67. PubMed ID: 27586020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of Amino Acid/Drug Transporters for Renal Transport of [
    Ono M; Baden A; Okudaira H; Kobayashi M; Kawai K; Oka S; Yoshimura H
    Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27754421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Raltegravir permeability across blood-tissue barriers and the potential role of drug efflux transporters.
    Hoque MT; Kis O; De Rosa MF; Bendayan R
    Antimicrob Agents Chemother; 2015 May; 59(5):2572-82. PubMed ID: 25691630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Drug Transport in MDCKII-Wild Type, MDCKII-MDR1, MDCKII-BCRP and Caco-2 Cell Lines.
    Mukkavilli R; Jadhav G; Vangala S
    Curr Pharm Biotechnol; 2017; 18(14):1151-1158. PubMed ID: 29521222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ochratoxin A transport by the human breast cancer resistance protein (BCRP), multidrug resistance protein 2 (MRP2), and organic anion-transporting polypeptides 1A2, 1B1 and 2B1.
    Qi X; Wagenaar E; Xu W; Huang K; Schinkel AH
    Toxicol Appl Pharmacol; 2017 Aug; 329():18-25. PubMed ID: 28532671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential selectivity of efflux transporter inhibitors in Caco-2 and MDCK-MDR1 monolayers: a strategy to assess the interaction of a new chemical entity with P-gp, BCRP, and MRP2.
    Mease K; Sane R; Podila L; Taub ME
    J Pharm Sci; 2012 May; 101(5):1888-97. PubMed ID: 22359351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elucidation of the Impact of P-glycoprotein and Breast Cancer Resistance Protein on the Brain Distribution of Catechol-
    Bicker J; Fortuna A; Alves G; Soares-da-Silva P; Falcão A
    Drug Metab Dispos; 2017 Dec; 45(12):1282-1291. PubMed ID: 28916530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TKI combination therapy: strategy to enhance dasatinib uptake by inhibiting Pgp- and BCRP-mediated efflux.
    D'Cunha R; Bae S; Murry DJ; An G
    Biopharm Drug Dispos; 2016 Oct; 37(7):397-408. PubMed ID: 27418107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.